Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.5% Following Analyst Upgrade

Eli Lilly and Company (NYSE:LLY – Get Free Report) shot up 1.5% on Tuesday after Jefferies Financial Group raised their price target on the stock from $1,610.00 to $1,700.00. Jefferies Financial Group currently has a buy rating on the stock. Eli Lilly and Company traded as high as $1,438.88 and last traded at $1,432.6010. Approximately 2,817,047 shares traded hands during mid-day trading, a decline of 5% from the average daily volume of 2,963,164 shares. The stock had previously closed at $1,411.95.

Several other equities research analysts have also commented on LLY. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Morgan Stanley boosted their price objective on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Sanford C. Bernstein reissued an “outperform” rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a report on Monday, October 26th. Weiss Ratings cut Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, October 30th. Finally, Scotiabank lifted their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,416.64.

Get Our Latest Stock Analysis on LLY

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by insiders.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

  • Positive Sentiment: Lilly reported positive Phase 3 results for its obesity pill Foundayo in obstructive sleep apnea: it reduced sleep-apnea breathing interruptions by up to an average of 44%. The company plans to seek U.S. approval for this additional use by year-end, potentially broadening the drug’s market beyond weight loss. Reuters: Lilly’s weight-loss pill meets main goal in late-stage sleep apnea study
  • Positive Sentiment: Jefferies raised its price target to $1,700 from $1,610 and maintained a Buy rating, signaling greater analyst optimism about Lilly’s prospects. MarketBeat: Jefferies price target update
  • Positive Sentiment: Lilly’s agreements with Hims & Hers and LifeMD are intended to widen nationwide digital access to branded Zepbound and Foundayo. This could expand prescription and delivery channels; the partnerships exclude compounded GLP-1 products. Yahoo Finance: Lilly opens digital access to obesity drugs
  • Negative Sentiment: The FDA is requiring makers of GLP-1 drugs to add a warning about a potential association with NAION, a rare eye condition that can cause sudden, sometimes permanent, vision loss. The labeling change could raise safety concerns among patients and prescribers, although the condition is rare. CNBC: FDA warns of vision loss risk linked to GLP-1 drugs

Hedge Funds Weigh In On Eli Lilly and Company

Large investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. State Street Corp boosted its holdings in shares of Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the period. Bank of America Corp DE purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after buying an additional 137,364 shares during the period. Finally, Jennison Associates LLC increased its stake in Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after buying an additional 400,538 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.5%

The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The company has a market cap of $1.35 trillion, a PE ratio of 46.50, a P/E/G ratio of 1.77 and a beta of 0.40. The business’s 50-day simple moving average is $1,220.13 and its 200-day simple moving average is $1,102.83.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same period in the previous year, the company posted $7.02 EPS. Eli Lilly and Company’s revenue was up 38.6% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 22.46%.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Further Reading

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.